- €9.49bn
- €9.62bn
- €1.89bn
Orion slips as Q1 falls short of expectations
Finland's Orion Q1 net sales rise on Nubeqa growth
Brief: Orion Q1 Oper. Profit Up At EUR 114.8 Million
Brief: Orion Pharma's ODM-212 Granted Orphan Drug Designation In Mesothelioma
Orion bottoms Helsinki blue chip index on Q4 profit miss
Brief: Orion Proposes Dividend Of EUR 1.80 For 2025
Europe Research Roundup: Aena, Fraport, Swedbank
European shares subdued as luxury stocks, miners weigh (updated)
Brief: Orion Expects Nubeqa Net Sales Over EUR 1 Bln By Decade's End
Orion expects cancer drug to drive 2026 sales growth, shares soar
Brief: Orion gives outlook for 2026
Brief: Orion Updates Full-Year Outlook For 2025
Orion falls as it posts Q3 miss, narrows 2025 guidance
Brief: Orion Says Tariffs Will Not Have An Impact On Co This Year
Advisory: Alert wrongly tagged to Orion SA withdrawn
Brief: Orion, Abzena Announce Exclusive Commercial License For Abzena's Antibody
Brief: Orion To Discontinue Development Of ODM-105 For Insomnia
Brief: Darolutamide Gets EU Approval for Third Prostate Cancer Indication
Brief: Orion Q2 Operating Profit EUR 104.6 Mln